COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: Synthesis, biological evaluation, and mechanism investigation

European Journal of Medicinal Chemistry

Volumn 56, Issue , 2012, Pages 17-29

  Chennamaneni, Snigdha ^a   Zhong, Bo ^a   Lama, Rati ^a   Su, Bin ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Anti cancer; COX inhibitor; Indomethacin; Sulindac; Tubulin inhibitor

Indexed keywords

INDOMETACIN; N (2 DIMETHYLAMINOETHYL) 1 (2 NAPHTHOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (3,4 DIMETHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (3,4,5 TRIMETHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (4 BROMOBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (4 METHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 DIMETHYLAMINOETHYL) 1 (PHENYLSULFONYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 METHOXYPHENYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 MORPHOLINOETHYL) 1 (3,4 DIMETHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 MORPHOLINOETHYL) 1 (3,4,5 TRIMETHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 MORPHOLINOETHYL) 1 (4 BROMOBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (2 MORPHOLINOETHYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (3 METHOXYPHENYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (4 CHLOROPHENYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (4 CHLOROPHENYL) 5 FLUORO 2 METHYL 1 [[4 (METHYLSULFINYL)PHENYL]METHYLENE] 1H INDENE 3 ACETAMIDE; N (4 IODOPHENYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (4 METHOXYPHENYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (4 METHOXYPHENYL) 5 FLUORO 2 METHYL 1 [[4 (METHYL SULFINYL)PHENYL]METHYLENE] 1H INDENE 3 ACETAMIDE; N (4 TOLYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N (N HEXYL) 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N [(2 PIPERIDIN 1 YL)ETHYL] 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N [2 (PYRROLIDIN 1 YL)ETHYL] 1 (3,4,5 TRIMETHOXYBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N [2 (PYRROLIDIN 1 YL)ETHYL] 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N PHENYL 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N,N' (1,5 PENTANEDIYL)BIS[1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE]; N,N' [1,4 PHENYLENEBIS(METHYLENE)]BIS[1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE]; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOMETHACIN; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SULINDAC;

EID: 84865544561     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.08.005     Document Type: Article

References (40)

1. J.R. Vane, and R.M. Botting Mechanism of action of antiinflammatory drugs Int. J. Tissue React. 20 1998 3 15
2. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J. Natl. Cancer Inst. 94 2002 252 266
3. T.A. Chan Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention Lancet Oncol. 3 2002 166 174
4. A. Agrawal, and I.S. Fentiman NSAIDs and breast cancer: a possible prevention and treatment strategy Int. J. Clin. Pract. 62 2008 444 449
5. R.E. Harris, J. Beebe-Donk, and G.A. Alshafie Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors BMC Cancer 6 2006 27 31
6. T. Iwama NSAIDs and colorectal cancer prevention J. Gastroenterol. 44 Suppl 19 2009 72 76
7. G.P. Boland, I.S. Butt, R. Prasad, W.F. Knox, and N.J. Bundred COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ Br. J. Cancer 90 2004 423 429
8. C.T. Dang, C.L. Shapiro, and C.A. Hudis Potential role of selective COX-2 inhibitors in cancer management Oncology (Williston Park) 16 2002 30 36
9. D. Mazhar, R. Gillmore, and J. Waxman COX and cancer Q. J. Med. 98 2005 711 718
10. B. Rigas, and K. Kashfi Cancer prevention: a new era beyond cyclooxygenase-2 J. Pharmacol. Exp. Ther. 314 2005 1 8
11. F.H. Sarkar, S. Adsule, Y. Li, and S. Padhye Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy Mini. Rev. Med. Chem. 7 2007 599 608
12. C.S. Williams, A.J. Watson, H. Sheng, R. Helou, J. Shao, and R.N. DuBois Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models Cancer Res. 60 2000 6045 6051
13. B. Su, M.V. Darby, and R.W. Brueggemeier Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer J. Comb. Chem. 10 2008 475 483
14. B. Zhong, X. Cai, S. Chennamaneni, X. Yi, L. Liu, J.J. Pink, A. Dowlati, Y. Xu, A. Zhou, and B. Su From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation Eur. J. Med. Chem. 47 2012 432 444
15. X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp, and C.S. Chen Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells J. Natl. Cancer Inst. 94 2002 585 591
16. J. Zhu, J.W. Huang, P.H. Tseng, Y.T. Yang, J. Fowble, C.W. Shiau, Y.J. Shaw, S.K. Kulp, and C.S. Chen From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res. 64 2004 4309 4318
17. X. Yi, B. Zhong, K.M. Smith, W.J. Geldenhuys, Y. Feng, J.J. Pink, A. Dowlati, Y. Xu, A. Zhou, and B. Su Identification of a class of novel tubulin inhibitors J. Med. Chem. 55 2012 3425 3435
18. V.E. Steele, R.C. Moon, R.A. Lubet, C.J. Grubbs, B.S. Reddy, M. Wargovich, D.L. McCormick, M.A. Pereira, J.A. Crowell, and D. Bagheri Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program J. Cell. Biochem. Suppl. 20 1994 32 54
19. A. Bennett, D.A. Berstock, and M.A. Carroll Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy Br. J. Cancer 45 1982 762 768
20. M. Pollard, and P.H. Luckert Prolonged antitumor effect of Indomethacin on autochthonous intestinal tumors in rats J. Natl. Cancer Inst. 70 1983 1103 1105
21. M. Moorghen, P. Ince, K.J. Finney, J.P. Sunter, D.R. Appleton, and A.J. Watson A protective effect of Sulindac against chemically-induced primary colonic tumors in mice J. Pathol. 156 1988 341 347
22. D.J. de Groot, E.G. de Vries, H.J. Groen, and S. de Jong Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic Crit. Rev. Oncol. Hematol. 61 2007 52 69
23. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu. Rev. Pharmacol. Toxicol. 38 1998 97 120
24. B.M. Gruber, I. Bubko, J. Krzyszton-Russjan, and E.L. Anuszewska Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms Med. Sci. Monit. 16 2011 BR45 51
25. A.M. Seo, S.W. Hong, J.S. Shin, I.C. Park, N.J. Hong, D.J. Kim, W.K. Lee, W.J. Lee, D.H. Jin, and M.S. Lee Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKβ Apoptosis 14 2009 913 922
26. D.J. de Groot, M. van der Deen, T.K. Le, A. Regeling, S. de Jong, and E.G. de Vries Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1 Br. J. Cancer 97 2007 1077 1083
27. L.H. Rome, and W.E. Lands Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs Proc. Natl. Acad. Sci. U. S. A. 72 1975 4863 4865
28. E.A. Meade, W.L. Smith, and D.L. Dewitt Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs J. Biol. Chem. 268 1993 6610 6614
29. G. Hawcraft, M.D. Amico, C. Albanese, A.F. Markhom, R.G. Pestell, and M.A. Kull Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells Carcinogenesis 23 2002 107 114
30. M.K. Jones, H. Wang, B.M. Peskar, E. Levin, R.M. Itani, I.J. Sarfels, and A.S. Tarnawski Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing Nat. Med. 5 1999 1418 1423
31. H.N. Tinsley, B.D. Gary, J. Thaiparambil, N. Li, W. Lu, Y. Li, Y.Y. Maxuitenko, A.B. Keeton, and G.A. Piazza Colon tumor cell growth-inhibitory activity of Sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition Caner Prev. Res. 3 2010 1303 1313
32. G. Sperl, P. Gross, K. Brendel, R. Pamuchu, G.A. Piazza, Preparation of substituted benzylideneindenylformamides, -acetamides and -propionamides for treatment of precancerous lesions and neoplasms, WO/97/47303.
33. G. Piazza, R. Reynolds, Preparation of Sulindac derivatives for treatment of precancerous conditions or cancer, WO/2007/081694.
34. A.S. Kalgutkar, B.C. Crews, S.W. Rowlinson, A.B. Marnett, K.R. Kozak, R.P. Remmel, and L.J. Marnett Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors Proc. Natl. Acad. Sci. U. S. A. 97 2000 925 930
35. H. Prinz, Y. Ishii, T. Hirano, T. Stoiber, J.A. Camacho Gomez, P. Schmidt, H. Düssmann, A.M. Burger, J.H. M.Prehn, E.G. Günther, E. Unger, and K. Umezawa Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization J. Med. Chem. 46 2003 3382 3394
36. T.L. Nguyen, C. McGrath, A.R. Hermone, J.C. Burnett, D.W. Zaharevitz, B.W. Day, P. Wipf, E. Hamel, and R. Gussio A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach J. Med. Chem. 48 2005 6107 6116
37. E. Hamel An overview of compounds that interact with tubulin and their effects on microtubule assembly T. Fojo, The Role of Microtubules in Cell Biology Neurobiology and Oncology 2008 Humana Press New Jersey 2 3
38. J. Löwe, H. Li, K.H. Downing, and E. Nogales Refined structure of αβ-tubulin at 3.5 Å resolution J. Mol. Biol. 313 2001 1045 1057
39. R. Bernini, F. Crisante, N. Merendino, R. Molinari, M.C. Soldatelli, and F. Velotti Synthesis of a novel ester of hydroxytyrosol and α-lipoic acid exhibiting an antiproliferative effect on human coloncancer HT-29 cells Eur. J. Med. Chem. 46 2011 439 446
40. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 30 2009 2785 2791